Transmedics Group Inc
NASDAQ:TMDX
Net Margin
Transmedics Group Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Transmedics Group Inc
NASDAQ:TMDX
|
4.2B USD |
10%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
234.1B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
198.4B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
157.6B USD |
12%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
148.8B USD |
12%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
110.8B USD |
13%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
54.8B EUR |
9%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
50.6B USD |
7%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
45.8B USD |
75%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
41.8B USD |
23%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
275B CNY |
31%
|
Transmedics Group Inc
Glance View
TransMedics Group Inc. emerged as a pioneering force within the medical technology sphere, aiming to revolutionize the organ transplant landscape. Founded with the bold vision of enhancing the viability of donor organs, TransMedics has developed the Organ Care System (OCS) — a portable, medical device designed to keep human organs alive and functioning outside of the body. The OCS effectively mimics the internal conditions of a human body, providing a nurturing environment that maintains organs in a near-living state. This innovation helps extend the time that organs can be viably transplanted, thereby increasing the success rates of transplants and offering a lifeline to individuals on long waiting lists. Monetizing this groundbreaking technology, TransMedics operates primarily through sales of its OCS products and related consumables, catering to well-established transplant centers worldwide. The company also taps into service agreements and training packages, ensuring that their clients can maximize the use and benefits of their products with the highest proficiency. In doing so, TransMedics not only empowers surgeons and hospitals to perform more successful transplants but also strengthens its position as a leading provider in a niche yet critical market. By addressing the challenges of organ preservation and transportation, TransMedics creates a compelling business model rooted in providing invaluable solutions for the healthcare industry and, ultimately, improving patient outcomes on a global scale.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Transmedics Group Inc's most recent financial statements, the company has Net Margin of 10%.
You don't have any saved screeners yet